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ABSTRACT: MAN1B1-CDG has recently been characterized as a type II
congenital disorder of glycosylation (CDG), disrupting not only protein
N-glycosylation but also general Golgi morphology. Using our high-
throughput, quantitative ultra-performance liquid chromatography assay, we
achieved a detailed characterization of the glycosylation changes in both total
serum glycoproteins and isolated serum IgG from ten previously reported
MAN1B1-CDG patients. We have identified and quantified novel hybrid high-
mannosylated MAN1B1-CDG-specific IgG glycans and found an increase of
sialyl Lewis x (sLex) glycans on serum proteins of all patients. This increase in
sLex has not been previously reported in any CDG. These findings may
provide insight into the pathophysiology of this CDG.
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■ INTRODUCTION
Glycosylation is an important post-translational modification
that has a significant influence on the biological functioning
of proteins. Glycoproteins are mixtures of glycosylated variants
in which a protein is modified by the attachment of a hetero-
geneous group of glycans at glycosylation sites. Glycan
processing pathways are complex and reflect the environment
both within and outside of the cells. These pathways are fre-
quently disrupted in diseases such as cancer, congenital dis-
orders of glycosylation, and chronic inflammatory diseases,
giving rise to aberrant or absent glycosylation of disease-related
proteins.1 Many glycoproteins present in human serum are
key components of the native and adaptive immune system.2
Immunoglobulins (IgGs) are important products of the
humoral immune response. Human serum IgG contains two
conserved N-linked glycosylation sites located in the Fc region
at Asn297 and variable glycosylation in the Fab region of ∼20%
of molecules.3
Congenital disorders of glycosylation (CDG) are a rapidly
expanding group of genetic diseases caused by defects in the
synthesis of glycoprotein and glycolipid glycans. Some 80 CDG
types are actually known (see Barone et al. 2014).4 They com-
prise a very broad range of phenotypes, including mostly
neurological involvement.5 CDG with abnormal N-glycosyla-
tion can be divided into CDG-I (defects in glycan assembly in
ER) and CDG-II (defects in glycan remodelling in the Golgi).
Most CDG have an autosomal-recessive inheritance; a few are
transmitted as dominant or X-linked disorders.6 The α(1,2)-
mannosidase (MAN1B1) catalyzes the removal of the terminal
mannose residue from the middle branch of Man9GlcNAc2
in the Golgi, thus generating the Man8GlcNAc2 isomer B
(Figure 1).7,8 Patients with defectiveMAN1B1 (MAN1B1-CDG)
usually show intellectual disability, obesity, and variable dys-
morphic features.5,8,9 It is a CDG-II, and the Golgi morphology is
altered in these patients’ cells.8
Structural analysis of N-linked glycans on serum glycopro-
teins in MAN1B1-deficient patients using mass spectrometry
showed an accumulation of hybrid-type glycans and some high
mannose structures.5,8 Analysis of N-glycans at the level of
intact transferrin indicated both hybrid type N-glycans with one
and two additional mannoses.5 Hybrid-type N-glycans were
also detectable in IgG and alpha1-antitrypsin in all patients
investigated.5
Among the methods used for glycan quantitation are high
performance and ultraperformance liquid chromatography
(HPLC and UPLC)-HILIC with fluorescence detection linked
with exoglycosidase sequencing.10,11 In addition, several bio-
informatics tools have been developed to assist the analyses, in-
cluding GlycoBase, a database with HILIC, and mass spectrometry
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data for 461 2-AB-labeled N-linked, 68 O-linked, and 71 free
glycan structures.11 The HPLC/UPLC analytical workflow has
been automated in a robotic 96-well plate format12,13 from
sample processing through to data interpretation.
In this study, we have analyzed glycosylation of whole serum
glycoproteins and serum IgG from ten previously reported
MAN1B1-CDG patients using our UPLC-HILIC technology
on a robotic platform to obtain a detailed overview of the glyco-
sylation changes.
■ MATERIALS AND METHODS
Serum Samples
Serum was used from ten previously reported MAN1B1-CDG
patients. Their phenotypes and genotypes are summarized in
Supplementary Table S1. Patients 2.1 and 2.2, and 6.1 and 6.2,
are siblings. A pooled serum sample (and isolated IgG from this
sample) from over 100 apparently healthy male and female
adult blood donors was used as a healthy control (courtesy of
the UK Blood Transfusion Service).
Sample Preparation
IgG glycan sample preparation was performed on an automated
glycomics platform as described in Stöckmann et al.,12 whereby
Figure 1. Location of MAN1B1 defect in the N-linked glycan biosynthetic pathway. Part of the affected pathway is pictured.7,8
Figure 2. Glycan nomenclature.
Figure 3. (A) Exoglycosidase digestions of the total N-linked glycan
pool of IgG isolated from patient 5; specific glycans for MAN1B1-CDG
are highlighted. (B) HILIC-UPLC chromatograms of the total N-linked
glycan pool of IgG isolated from all patients. Samples are colored based
on similarity (patients with similarities with the healthy control are
colored in black, and patients from the two sets sharing similarities to
each other are colored in red). Significantly increased peaks are
highlighted with arrows, and their compositions are listed in Table 1.
MAN1B1-CDG-specific glycans in major affected peaks are highlighted.
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Table 1. N-Glycan Composition of 26 Peaks in Patient Serum IgG Samplesa
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IgG was affinity-purified with PhyTips or Protein G plates using
an updated automated serum glycomics platform described by
Stöckmann et al.13 for whole serum glycan sample preparation
and analysis (see Supporting Information). Glycans were fluo-
rescently labeled with 2-aminobenzamide (2AB) by reductive
amination.14 Samples were analyzed in duplicate.
HILIC-UPLC
HILIC-UPLC was carried out on a BEH Glycan 1.7 μM 2.1 ×
150 mm column (Waters, Milford, MA) on an Acquity UPLC
(Waters, Milford, MA) equipped with a Waters temperature
control module and a Waters Acquity fluorescence detector.
Solvent A was 50 mM formic acid adjusted to pH 4.4 with
ammonia solution. Solvent B was acetonitrile. The column
temperature was set to 30 °C. The following conditions were
used: 30 min method using a linear gradient of 30−47% A at
0.56 mL/min in 23 min. Samples were injected in 70% aceto-
nitrile. Fluorescence was measured at 420 nm with excitation at
330 nm. The system was calibrated using an external standard
of hydrolyzed and 2AB-labeled glucose oligomers to create
a dextran ladder with retention times of all identified peaks
expressed as glucose units (GU), as described previously by
Royle et al.15
Glycan Nomenclature
All N-glycans have two core GlcNAcs (Figure 2); F at the start
of the abbreviation indicates a core α(1,6)-fucose linked to the
inner GlcNAc; Mx, number (x) of mannose on core GlcNAcs;
Ax, number of antenna (GlcNAc) on trimannosyl core; A2,
biantennary with both GlcNAcs as β(1,2)-linked; A3,
triantennary with a GlcNAc linked β(1,2)- to both mannose
and a third GlcNAc linked β(1,4)- to the α(1,3)-linked man-
nose; A4, GlcNAcs linked as A3 with additional GlcNAc
β(1,6)-linked to α(1,6)-mannose; Gx, number (x) of β(1,4)-
linked galactose on the antenna; Sx, number (x) of sialic acids
linked to galactose; the number 3 or 6 in parentheses after
S indicates whether the sialic acid is in an α(2,3)- or α(2,6)-
linkage.
Exoglycosidase Digestion
All enzymes were purchased from Prozyme (San Leandro, CA,
USA) or New England Biolabs (Ipswich, MA, USA). The 2AB-
labeled glycans were digested in a volume of 10 μL for 18 h at
37 °C in 50 mM sodium acetate buffer, pH 5.5 (except in the
case of jack bean α-mannosidase (JBM), where the buffer was
100 mM sodium acetate, 2 mM Zn2+, pH 5.0), using arrays of
the following enzymes: Arthrobacter ureafaciens sialidase (ABS,
Table 1. continued
aIsomer (i) of the structure. In red are highlighted glycans specific for MAN1B1-CDG on IgG and peaks containing them in major traces; GPs in red
contain these specific glycans as the most abundant structures.
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EC 3.2.1.18), 0.5 U/mL; bovine testes β-galactosidase (BTG,
EC 3.2.1.23), 1 U/mL; bovine kidney α-fucosidase (BKF, EC
3.2.1.51), 1 U/mL; β-N-acetylglucosaminidase cloned from
S. pneumonia, expressed in Escherichia coli (GUH, EC 3.2.1.30),
4 U/mL; JBM (EC 3.2.1.24), 60 U/mL; almond meal α-fucosidase
(AMF, EC 3.2.1.111), 0.4 mU/mL. After incubation, enzymes
were removed by filtration through 10 kDa protein-binding
EZ filters (Millipore Corporation).15 N-Glycans were then
analyzed by UPLC.
■ RESULTS
N-Glycan Profiles of Serum IgG from MAN1B1-CDG
Patients
Our high-throughput N-glycan analysis platform was utilized
for IgG glycan analysis.12 The N-glycan pool released from
IgG was separated into 26 peaks and assigned based on
exoglycosidase digestions according to Pucic et al.,16 whereby
our HILIC-UPLC technology was used to assign the IgG
N-glycome in detail (Figure 3A, Table 1).
Table 2. Percent Areas of 26 Peaks in Patient Serum IgG Samplesa
sample GP1 GP2 GP3 GP4 GP5 GP6 GP7 GP8 GP9 GP10 GP11
control 0.38 0.72 1.14 23.55 5.76 0.56 0.90 20.84 9.06 5.04 0.85
1 0.30 1.16 0.33 9.87 3.61 0.34 0.10 12.47 3.74 4.41 0.37
2.1 0.07 0.65 0.29 6.52 2.11 0.34 0.07 12.20 3.37 3.97 0.18
2.2 0.24 0.33 0.44 21.96 3.80 0.25 0.13 20.68 6.06 3.04 0.33
3 0.12 0.32 0.52 16.61 2.72 0.29 0.16 21.23 7.26 3.51 0.37
4 0.22 2.24 0.63 14.08 3.60 0.89 0.58 12.08 6.44 3.91 0.57
5 0.14 0.87 0.49 10.13 1.43 0.51 0.56 11.57 4.42 2.69 0.46
6.1 0.16 1.05 0.45 11.38 2.04 0.42 0.53 10.29 3.32 3.22 0.52
6.2 0.22 1.72 0.65 16.93 2.29 1.02 0.63 12.82 6.95 2.91 0.58
7 0.15 1.12 0.55 9.32 1.87 0.90 0.69 11.82 4.77 3.05 0.52
8 0.16 1.41 0.60 11.31 2.40 0.75 0.59 12.68 5.63 3.53 0.49
sample GP12 GP13 GP14 GP15 GP16 GP17 GP18 GP19 GP20 GP21
control 0.97 0.18 15.96 1.47 0.34 1.71 0.97 0.23 6.15 1.14
1 0.72 2.49 16.41 1.50 0.71 4.14 9.99 1.12 11.60 9.08
2.1 0.60 1.60 17.73 1.66 0.86 4.27 9.20 1.20 14.69 10.88
2.2 0.56 0.22 14.75 0.71 0.72 2.91 1.25 0.18 15.02 0.87
3 0.32 0.53 16.15 1.13 0.52 2.73 2.89 0.60 10.92 4.65
4 0.93 2.33 13.71 1.44 0.74 4.29 6.48 1.00 7.64 8.53
5 0.56 1.45 15.94 1.27 0.90 4.24 10.16 1.02 11.81 13.24
6.1 0.47 1.84 15.26 1.43 0.88 4.01 11.19 0.89 14.31 8.75
6.2 0.99 2.12 16.53 1.23 0.66 3.19 8.03 0.92 7.93 5.51
7 1.12 1.78 18.43 1.34 0.94 3.24 11.63 0.96 11.98 7.21
8 0.77 2.01 15.38 1.32 0.87 4.55 7.74 0.87 11.16 9.32
sample GP22 GP23 GP24 GP25 GP26
control 0.10 0.66 0.06 0.61 0.65
1 0.63 2.16 0.26 1.53 1.04
2.1 0.58 1.74 0.39 2.76 2.14
2.2 0.28 2.14 0.08 1.98 1.13
3 0.21 1.28 0.19 2.60 2.26
4 0.83 2.01 0.39 2.20 2.23
5 0.62 1.38 0.35 2.39 1.38
6.1 0.85 1.74 0.39 2.88 1.71
6.2 1.11 2.28 0.27 1.40 1.13
7 1.00 2.53 0.42 1.67 1.01
8 0.70 1.58 0.30 2.20 1.67
sample G0 G1 G2 S1 S2
control 31.55 37.25 18.58 10.64 1.98
1 15.26 21.42 21.11 37.26 4.98
2.1 9.62 20.13 21.58 41.68 7.02
2.2 20.28 32.80 18.13 22.50 6.31
3 26.77 30.48 16.24 21.22 5.32
4 20.78 24.46 18.41 29.51 6.83
5 13.06 20.21 19.23 41.99 5.50
6.1 21.82 24.91 20.86 27.33 5.08
6.2 15.88 23.67 19.48 35.22 5.74
7 13.01 21.75 22.67 36.95 5.62
8 15.09 18.31 19.00 40.88 6.72
aItalics indicates more than 100% increase in percent area and bold indicates more than 100% decrease in percent area of peaks in patients compared
to healthy controls. Glycans are separated based on features: nongalactosylated = G0 = GP1−5; monogalactosylated = G1 = GP6−11;
digalactosylated = G2 = GP12−15; monosialylated = S1 = GP16−21; disialylated = S2 = GP23−26.
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Figure 3B shows UPLC chromatograms of N-glycan pools
from all patients compared to those of the healthy control pool.
The most significant observation is that peaks GP 2, 13, 17, 18,
19, 21, and 22 (Table 1, high abundance of hybrid MAN1B1-
CDG specific glycans) are significantly increased in all patients
except for patient 2.2 and patient 3 (Figure 3B and Table 2)
compared to those of the healthy control. These two patients
have consistently lower amounts of these glycans compared to
the other patients, and the amounts are almost comparable to
the healthy control levels (Table 3). MAN1B1-CDG-specific
glycans were quantified by digestion of the glycan pool with
sialidase and β-galactosidase and with sialidase, β-galactosidase,
bovine kidney α-fucosidase, and β-N-acetylglucosaminidase
because otherwise they coelute together with other N-glycans
in the undigested pool. The total amount was calculated from
the sum of specific glycans after digestion with sialidase and
β-galactosidase digest (FA1i) and specific glycans after diges-
tion with sialidase, β-galactosidase, bovine kidney α-fucosidase,
and β-N-acetylglucosaminidase (M4i+M5i+M6i+M9i) (Table 3).
These specific glycans were identified in major amounts in the
following peaks (see Table 1): FA1i in GP2, FA1iG1 in GP6,
M5iA1 in GP7, M5iA2 and FM5iA1 in GP10, FM4iA1G1
in GP11, M6iA1, FA1iG1S(6)1, FM5iA1G1 and M5iA2G1 in
GP15, FM5iA2G1 and M6iA1G1 in GP17, M5iA2G2 and
FM4iA1G1S(6)1 in GP18, FM6iA1G1 and M5iA1G1S(6)1
in GP19, FM5iA1G1S(6)1 and M5iA2G1S(6)1 in GP21,
FM5iA2G1S(6)1 in GP22, and FM5iA2G2S(6)1 in GP26. The
specific glycans were also present in minor amounts in the
following peaks (see Table 1): FM4i in GP4, M4iA1G1 in GP8,
M6iA1, FM5iA2 and M5iA1G1 in GP13, M4A1G1S(6)1
in GP16, FM5iA2G2 in GP20, and M9i in GP23. MAN1B1-
CDG-specific isomer (mannose not cleaved) of normal manno-
sylated glycans is indicated by i.
N-Glycan Profiles of Total Serum Glycoproteins from
MAN1B1-CDG Patients
Our updated version of high-throughput N-glycan analysis
platform was utilized for serum glycan analysis.13 The N-glycan
pool released from serum was separated into 46 peaks and
assigned based on Saldova et al.17 and exoglycosidase digests
(Figure 4A, Table 4).
Figure 4B shows N-glycan pools from all patients compared
to that of the healthy control. The most significant observation
is an increase in high mannose glycans in all patients except for
patient 2.2 and an increase in glycans containing the sLex epitope
(triantennary trigalactosylated outer arm fucosylated trisialylated
glycans, Figure 5) in all patients (Figure 4B, Table 5) compared
to the healthy control. Also, there seems to be a decrease in
simple glycans at the beginning of the profile and an increase in
highly branched and sialylated glycans at the end of the profile
in patients compared to those of the healthy control (Table 5).
MAN1B1-CDG specific glycans were quantified by digestion
of the glycan pool with sialidase and β-galactosidase and with
sialidase, β-galactosidase, bovine kidney α-fucosidase, and
β-N-acetylglucosaminidase. The total was calculated from the
sum of specific glycans after digestion with sialidase and
β-galactosidase (digest FA1i) and specific glycans after sialidase,
β-galactosidase, bovine kidney α-fucosidase, and β-N-acetylglu-
cosaminidase (M4i+M5i+M6i+M7i+M8i+M9). All patients
except for patient 2.2 have significantly higher amounts of the
MAN1B1-CDG-specific glycans compared to those of the healthy
control (Table 6, quantified after exoglycosidase digestion).
SLex-containing glycans were separated and quantified after
digesting the glycan pool with sialidase and β-galactosidase.
After the digestions, the sialylated α(1,3)-fucosylated trianten-
nary and tetraantennary sialylated structures formed the α(1,3)-
fucosylated monogalactosylated triantennary structure (A3F1G1),
Table 3. Sum of Specific IgG MAN1B1-CDG N-Glycans for
All Samplesa












aThe percent areas were calculated from ABS+BTG (FA1i) and
ABS+BTG+BKF+GUH (all Mi = M4i+M5i+M6i+M9i) digests (best
separation for quantification). Percent area of unique MAN1B1-CDG
N-glycans= FA1i+M4i+M5i+M6i+M9i (Figure 3). Figure 4. (A) Exoglycosidase digestions of the total N-linked glycan
pool of serum isolated from patient 8. Specific glycans for MAN1B1-
CDG and sLex epitope-containing glycans are highlighted. (B) HILIC-
UPLC chromatograms of the total N-linked glycan pool of serum from
all patients. The healthy control sample was obtained from another
project. Samples are colored based on similarity (control in blue,
patients more similar to control−at the beginning of the profile−are in
black, and patients from the two sets similar to each other are in red).
Significantly increased peaks are highlighted and their composition is
in Table 4. Major glycans in affected peaks are highlighted
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Table 4. Predominant N-Glycans in 46 Peaks in CDG Serum Samples
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α(1,3)-fucosylated monogalactosylated tetraantennary structure
(A4F1G1), and α(1,3)-difucosylated digalactosylated tetraan-
tennary structure (A4F2G2). These digestion products elute as
clear baseline-separated peaks, allowing accurate quantification
by the percent area under each peak (Figure 4A). Total sLex is
the sum of the three peaks that contain the sLex epitope
(A3F1G1+A4F1G1+A4F2G2) (Table 6). The glycans contain-
ing sLex epitopes were increased in all patients compared to
healthy controls (Table 6).
■ DISCUSSION
The present paper focuses on a detailed characterization of
the full repertoire of MAN1B1 glycans on serum IgG and
serum glycoproteins and extends these findings to the identifi-
cation of glycan abnormalities beyond the direct functional
loss of MAN1B1 deficiency. These patients were analyzed by
Rymen et al.8 and Van Scherpenzeel et al.,5 who found
MAN1B1-CDG-specific glycans (hybrid, high mannosylated
glycans) both on serum glycoproteins and isolated IgG.
Namely, Rymen et al. found accumulation of M5A1G1S1,
FM5A1G1S1, M4A1G1S1, FM4A1G1S1, and M6 in serum
of MAN1B1-CDG patients.8 Van Scherpenzeel et al. found
M4A1G1S1 and M5A1G1S1 in transferrin, M6, M4A1G1S1,
M5A1G1S1, and FM5A1G1S1 on serum glycoproteins, and
hybrid-type high mannose glycans in IgG and alpha1-antitrypsin.5
In addition, we have identified other specific IgG glycosylation
abnormalities typical for MAN1B1-CDG using our high-
throughput quantitative and sensitive technique (Table 1). The
abnormal glycans contain high mannosylated hybrid glycans,
mostly penta- and hexamannosylated glycans with one or two
antennas and one or two galactose residues; some are mono-
sialylated (Table 1). We have quantified the total amounts of the
specific MAN1B1-CDG-specific glycoforms in both serum and
IgG in all patients (Tables 2 and 5). The patterns of two patients,
2.2 and 3, are comparable to that of the control profile (Figure 3B
and Table 3).
Previously unreported MAN1B1-CDG structures found in
the present study highlight the sensitivity and high-resolution of
the UPLC-HILIC technology. Matrix-assisted laser desorption/
ionization (MALDI) mass spectrometry used in Rymen
et al.8 and Van Scherpenzeel et al.5 is a different technique;
furthermore, selection of the structures depends on a search of
specific masses corresponding to glycans, whereas with the
UPLC-HILIC technique, the glycans are fluorescently labeled
and therefore all visible in the spectra.
We have also found an increase in sLex-containing glycans in
sera of all patients. This has not been reported before in
MAN1B1 or any other CDG (Figure 4B, Table 6). An increase
in the sLex epitope has been found on acute phase proteins in
inflammation and cancer.18 This may possibly indicate that
MAN1B1-CDG is associated with some inflammatory activity,
although infections/inflammations are not part of these
patients’ phenotype. The reason for the increase in sLex may
be a disruption of Golgi morphology in these patients. Golgi
pH is dysregulated in cancer and interestingly, also in another
CDG-II, ATP6 V0A2-CDG.19 Altered Golgi morphology in
MAN1B1-CDG may lead to dysregulation of Golgi pH leading
to glycosylation defects, including the presence of the sLex
epitope. Some glycosylation events are sensitive to Golgi pH
changes, such as α(2,3)-sialylation, which is affected by a
slight Golgi pH increase.19 The increased level of sLex glycans
(containing α(2,3)-sialic acid) in MAN1B1 patients may origi-
nate in disruption of Golgi morphology in these patients.
Glycans play various biological roles on glycoproteins, e.g., in
protein folding, trafficking, ligand recognition, biological activity,
stability, and regulating protein half-life and immunogenicity.20
Glycosylation on immunoglobulin G has a significant impact on
immune function. The absence of core fucose and the presence
of bisecting GlcNAc on IgG enhances antibody-dependent cell-
mediated cytotoxicity (ADCC) activity,21,22 whereas sialic acid
on IgG suppresses ADCC activity.23 Galactose is important for
placental transport.24 GlcNAc and mannose are ligands for
mannose binding lectin and enhance complement-dependent
cytotoxicity (CDC).25 IgG glycans also have a significant impact
on binding to FcγR and the subsequent immune responses.26
Sialic acids are also biologically important, not only in quantity,
but also the structure, linkage, class, and spatial organization.27,28
Siglecs are immunoglobulin-like lectins binding sialic acids, and
they are involved in cell−cell interactions and signaling functions
in the hemopoietic, immune, and nervous systems in signaling
and adhesion29 and are species-specific.28 They are important in
host-defense because sialic acids are species-specific and absent
from many pathogens.29 The pathogens either synthesize or
acquire sialic acids from the host and use siglecs to manipulate
the host immune response.30 The virulent parasite Leishmania sp.
contains higher amounts of sialic acids.31 Modification of sialic
acids, such as O-acetylation, also play a role in its virulence.31
α(2,6)-Sialylation mediates tumor progression via enhanced β1-
integrin function and is associated with poor prognosis.32 Sialic
acids have important roles in immunity, such as modulation of
leukocyte trafficking via selectins, ligands for microbes, pathogen
molecular mimicry of host sialic acids, polysialic acid modulation
of immune cells, modulation of immunity by sialic acid O-
acetylation, as antigens and xeno-autoantigens, antisialoglycan
antibodies in reproductive incompatibility, and sialic acid-based
blood groups.33 sLex is a key component of sialylated selectin
ligands and of preferred ligands for some siglecs.33
These findings, i.e., the increase in MAN1B1-CDG specific
and sLex glycans, could lead to disruption of a wide range of
body systems leading to these patients’ phenotypes.
In summary, our work has demonstrated specific glycan
abnormalities for MAN1B1-CDG, partially corresponding with
the deficient enzymatic activity of Golgi α(1,2)-mannosidase,
but additional observed glycan structures are possibly related to
other functions of MAN1B1.
Figure 5. Illustration of Lewis x and sialyl Lewis x epitopes and the
digestion products of serum glycans containing these epitopes after
digestion with sialidase and β-galactosidase.
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Table 5. Percent Areas of 46 Peaks in CDG Serum Samplesa
sample GP1 GP2 GP3 GP4 GP5 GP6 GP7 GP8 GP9 GP10 GP11
control 0.07 0.13 0.03 0.22 4.02 2.19 0.16 4.05 1.69 1.24 1.23
1 0.08 0.03 0.12 0.07 0.81 0.74 0.02 0.99 0.29 2.24 0.55
2.1 0.08 0.17 0.02 0.06 0.84 0.74 0.05 1.53 0.42 1.87 0.57
2.2 0.04 0.03 0.07 0.04 3.17 1.66 0.08 2.94 0.84 0.72 0.95
3 0.04 0.07 0.06 0.06 2.55 0.99 0.07 3.35 1.12 1.99 0.78
4 0.07 0.18 0.05 0.04 1.14 0.68 0.09 1.29 0.48 1.85 0.37
5 0.03 0.05 0.04 0.01 0.40 0.24 0.06 0.93 0.34 0.87 0.19
6.1 0.04 0.07 0.04 0.03 0.53 0.43 0.09 0.95 0.30 1.65 0.29
6.2 0.05 0.07 0.04 0.03 0.54 0.34 0.08 0.78 0.23 1.51 0.26
7 0.02 0.03 0.02 0.01 0.24 0.21 0.05 0.64 0.18 0.89 0.19
8 0.04 0.07 0.03 0.02 0.60 0.29 0.06 1.05 0.36 0.99 0.20
sample GP12 GP13 GP14 GP15 GP16 GP17 GP18 GP19 GP20 GP21
control 0.51 0.10 3.95 0.62 1.08 0.73 0.05 7.62 0.21 0.67
1 0.40 0.24 1.63 0.66 1.97 0.44 0.22 3.11 0.25 6.17
2.1 0.31 0.25 2.68 0.78 1.95 0.68 0.22 4.98 0.24 6.88
2.2 0.43 0.04 2.51 0.29 1.17 0.51 0.05 4.92 0.13 0.38
3 0.38 0.15 2.83 0.88 1.93 0.48 0.18 4.84 0.24 5.95
4 0.74 0.70 2.68 1.11 2.34 1.43 0.30 6.61 0.90 6.91
5 0.48 0.42 2.95 0.78 1.95 1.29 0.21 6.74 0.70 7.39
6.1 0.67 0.67 2.82 1.02 2.50 1.21 0.34 8.50 0.98 7.36
6.2 0.68 0.63 1.91 1.02 2.33 1.00 0.29 7.49 1.06 7.57
7 0.51 0.43 2.16 0.75 1.99 0.88 0.19 6.10 0.86 6.55
8 0.49 0.54 2.79 0.81 1.99 1.40 0.28 6.27 0.85 6.64
sample GP22 GP23 GP24 GP25 GP26 GP27 GP28 GP29 GP30 GP31
control 5.45 2.24 4.39 32.63 1.32 4.18 2.23 1.39 0.12 0.69
1 2.45 2.22 3.25 37.05 0.90 2.58 0.68 0.85 0.10 0.43
2.1 4.47 3.59 3.11 33.85 1.25 4.64 2.96 0.97 0.06 0.67
2.2 4.75 0.82 4.66 37.98 0.99 3.38 0.70 1.02 0.07 0.61
3 3.82 2.46 3.08 36.52 1.04 4.00 1.86 0.76 0.08 0.48
4 5.24 5.30 2.60 29.74 0.79 4.91 2.47 1.40 0.28 0.89
5 6.59 6.58 2.01 25.44 0.93 8.48 3.18 1.47 0.29 0.96
6.1 6.47 4.20 2.86 31.84 0.93 4.24 1.76 1.57 0.30 1.12
6.2 4.52 3.35 3.63 35.59 0.88 2.98 1.01 1.66 0.32 1.01
7 4.95 3.42 2.90 33.29 0.91 3.11 0.88 1.64 0.49 1.06
8 6.27 5.23 2.11 27.96 1.04 6.80 3.60 1.49 0.30 1.17
sample GP32 GP33 GP34 GP35 GP36 GP37 GP38 GP39 GP40 GP41
control 0.27 0.80 6.21 0.30 0.46 1.62 2.43 0.30 0.27 0.80
1 0.51 0.61 6.95 0.44 0.32 3.28 7.12 0.41 0.50 0.79
2.1 0.33 0.59 5.63 0.32 0.22 2.00 5.43 0.27 0.30 0.46
2.2 0.39 0.93 7.26 0.60 0.45 1.91 7.76 0.38 0.62 0.44
3 0.36 0.40 4.07 0.29 0.22 1.54 4.67 0.34 0.35 0.57
4 0.89 0.85 4.92 0.45 0.41 2.29 3.82 0.41 0.43 0.42
5 1.05 0.84 4.62 0.49 0.50 2.00 4.89 0.62 0.66 0.56
6.1 0.74 0.82 5.10 0.34 0.33 1.98 2.80 0.31 0.29 0.38
6.2 0.91 0.98 5.64 0.56 0.30 2.04 4.20 0.32 0.38 0.43
7 1.20 1.15 6.93 0.63 0.36 3.46 6.16 0.49 0.50 0.71
8 0.86 0.92 5.53 0.41 0.47 2.95 3.90 0.61 0.45 0.50
sample GP42 GP43 GP44 GP45 GP46
control 0.47 0.56 0.26 0.28 0.23
1 1.01 1.61 1.33 2.19 1.53
2.1 0.56 0.86 0.61 0.95 0.67
2.2 0.56 0.74 0.59 0.89 0.66
3 0.56 0.98 0.66 1.13 0.92
4 0.26 0.43 0.26 0.37 0.20
5 0.27 0.47 0.30 0.44 0.28
6.1 0.21 0.36 0.19 0.24 0.13
6.2 0.27 0.42 0.24 0.33 0.17
7 0.47 0.73 0.50 0.73 0.44
8 0.26 0.48 0.28 0.40 0.25
aItalics indicate more than 100% increase, and bold indicates more than 100% decrease in percent area of peaks in patients compared to healthy
controls.
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